Regeneus (ASX:RGS), today announced that Progenza has been granted an Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA), following consultation with the European Commission.
Progenza is the company's allogeneic stem cell technology platform for the treatment of osteoarthritis and other inflammatory conditions for human applications.
'The granting of the ATMP classification for Progenza, is a step towards bringing Progenza to Europe as a novel cell therapy treatment for osteoarthritis. It's important to have regulatory clarity as we invest in the development of Progenza,' said John Martin, CEO of Regeneus.
Regeneus Ltd. published this content on 14 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 February 2018 23:00:04 UTC.